Received: October 16, 2008; Accepted: November 8, 2008.
Share :
ABSTRACT
Purpose: To date, the principles of treatment for patients with recurrent gastric cancer after curative resection have not
been suggested, and most centers have managed them according to their experience. Therefore, we investigated current practice
of management for recurrence after curative resection for gastric cancer through nationwide survey in Korea which is
high incidence area.
Materials and Methods: From July to September 2007, a questionnaire was sent out to 205 members of Korean Gastric
Cancer Association (KGCA). A questionnaire was composed of cover letter, general information and main questionnaire about
follow-up schedules and contents.
Results: Forty-six percent (96/205) of the members of the KGCA returned the survey. Most common responders described
that TS-1 was used for single chemotherapeutic agent for recurrent gastric cancer. Cisplatin combined with oral or intravenous
5-FU was commonly used as complex regimen. In treatment modality according to recurrent sites, the systemic chemotherapy
was commonly used for patients with peritoneal or local recurrence. In case of single metastasis in liver, most physicians
answered that resection was applied for them, if at all possible.
Conclusion: It seems that clinicians remain variable regarding how to treat the patients with recurrence after curative resection
for gastric cancer. Therefore, a multicenter randomized trial is needed to confirm the treatment modality according to
recurrent sites, and our results could give an aid to design such study.